Association between aspirin use and mortality in breast cancer patients: a meta-analysis of observational studies

Breast Cancer Research and Treatment

Volumn 150, Issue 1, 2015, Pages 199-207

  Zhong, Shanliang ^a   Zhang, Xiaohui ^a   Chen, Lin ^b   Ma, Tengfei ^a   Tang, Jinhai ^a   Zhao, Jianhua ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Aspirin; Breast; Cancer; Outcome; Prognosis; Survival

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CASE CONTROL STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG USE; FOLLOW UP; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME; BREAST NEOPLASMS; COHORT ANALYSIS; FEMALE; MORTALITY; ODDS RATIO;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; ODDS RATIO; RISK FACTORS;

EID: 84925491608     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3300-z     Document Type: Article

References (31)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. doi:10.3322/caac.21208
2. Blair CK, Sweeney C, Anderson KE, Folsom AR (2007) NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat 101(2):191–197. doi:10.1007/s10549-006-9277-x
3. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE (2010) Aspirin intake and survival after breast cancer. J clin oncol 28(9):1467–1472. doi:10.1200/jco.2009.22.7918
4. Fraser DM, Sullivan FM, Thompson AM, McCowan C (2014) Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br J Cancer 111(3):623–627. doi:10.1038/bjc.2014.264
5. Thorat MA, Cuzick J (2013) Role of aspirin in cancer prevention. Curr Oncol Rep 15(6):533–540. doi:10.1007/s11912-013-0351-3
6. Ye XF, Wang J, Shi WT, He J (2014) Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies. Br J Cancer. doi:10.1038/bjc.2014.481
7. Wells G, Shea B, O’Connell D, Robertson J, Peterson J, Welch V, Losos M, Tugwell P (2010) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. www.ohri.ca/programs/clinical_epidemiology/oxford_web.ppt
8. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188. doi:10.1016/0197-2456(86)90046-2
9. Holmes MD, Olsson H, Pawitan Y, Holm J, Lundholm C, Andersson TM, Adami HO, Askling J, Smedby KE (2014) Aspirin intake and breast cancer survival—a nation-wide study using prospectively recorded data in Sweden. BMC Cancer 14(1):391. doi:10.1186/1471-2407-14-391
10. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. doi:10.1002/sim.1186
11. Hedges LV, Pigott TD (2001) The power of statistical tests in meta-analysis. Psychol Methods 6(3):203–217
12. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634
13. Bardia A, Ebbert JO, Vierkant RA, Limburg PJ, Anderson K, Wang AH, Olson JE, Vachon CM, Cerhan JR (2007) Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst 99(11):881–889. doi:10.1093/jnci/djk200
14. Allott EH, Tse CK, Olshan AF, Carey LA, Moorman PG, Troester MA (2014) Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study. Breast Cancer Res Treat 147(2):415–421. doi:10.1007/s10549-014-3099-z
15. Chan AT, Manson JE, Feskanich D, Stampfer MJ, Colditz GA, Fuchs CS (2007) Long-term aspirin use and mortality in women. Arch Intern Med 167(6):562–572
16. Holmes MD, Chen WY, Schnitt SJ, Collins L, Colditz GA, Hankinson SE, Tamimi RM (2011) COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat 130(2):657–662. doi:10.1007/s10549-011-1651-7
17. Holmes MD, Hankinson SE, Feskanich D, Chen WY (2013) Beta blockers and angiotensin-converting enzyme inhibitors’ purported benefit on breast cancer survival may be explained by aspirin use. Breast Cancer Res Treat 139(2):507–513. doi:10.1007/s10549-013-2553-7
18. Barron TI, Sharp L, Bennett K, Visvanathan K (2012) Aspirin use and mortality in women with stage I–III breast cancer: A population-based study. J Clin Oncol 30(suppl;abstr 521). http://meetinglibrary.asco.org/content/99184-114
19. Fraser D, Sullivan F, McCowan C (2013) Relationship between aspirin use after diagnosis of breast cancer and survival in a cohort of Scottish women. Eur J Surg Oncol 39(5):522
20. Jonsson F, Yin L, Lundholm C, Smedby KE, Czene K, Pawitan Y (2013) Low-dose aspirin use and cancer characteristics: a population-based cohort study. Br J Cancer 109(7):1921–1925. doi:10.1038/bjc.2013.411
21. Schapira DV, Theodossiou C, Lyman GH (1999) The effects of NSAIDs on breast cancer prognostic factors. Oncol Rep 6(2):433–435
22. Chae Y, Hong DS, Kim KH, Falchook GS, Piha-Paul SA, Subbiah V, Zinner RG, Kurzrock R, Wolff RA, Janku F (2013) PIK3CA mutations, aspirin use and mortality in patients with women’s cancers or colorectal cancers treated in early-phase clinical trials. Eur J Cancer 49:S313–S314
23. Higgins MJ, Chapman JAW, Ingle JN, Sledge G, Budd GT, Ellis MJ, Pritchard KI, Clemons M, Badovinac CT, Han L, Gelmon K, Rabaglio M, Elliott C, Shepherd LE, Goss PE (2012) Effect of aspirin (ASP) or celecoxib (CC) use on outcomes in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: nCIC CTG MA. 27. Cancer Res 72(24):2–13
24. Bond S (2010) Aspirin use is associated with decreased risk of breast cancer recurrence and death. J midwifery women’s health 55(4):389–390. doi:10.1016/j.jmwh.2010.04.002
25. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW (1993) Aspirin use and risk of fatal cancer. Cancer Res 53(6):1322–1327
26. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E (2004) Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 24(5b):3177–3184
27. Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA (2011) Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf 20(2):131–137. doi:10.1002/pds.2064
28. Li Y, Brasky TM, Nie J, Ambrosone CB, McCann SE, Shields PG, Trevisan M, Edge SB, Freudenheim JL (2012) Use of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 21(1):239–242. doi:10.1158/1055-9965.epi-11-1012
29. Barron TI, Flahavan EM, Sharp L, Bennett K, Visvanathan K (2014) Recent prediagnostic aspirin use, lymph node involvement, and 5-Year mortality in women with stage I–III breast cancer: a nationwide population-based cohort study. Cancer Res 74(15):4065–4077. doi:10.1158/0008-5472.can-13-2679
30. Murray LJ, Cooper JA, Hughes CM, Powe DG, Cardwell CR (2014) Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink. Breast Cancer Res 16(2):R34. doi:10.1186/bcr3638
31. Jacobo-Herrera NJ, Perez-Plasencia C, Camacho-Zavala E, Gonzalez GF, Urrutia EL, Garcia-Castillo V, Zentella-Dehesa A (2014) Clinical evidence of the relationship between aspirin and breast cancer risk (review). Oncol Rep 32(2):451. doi:10.3892/or.2014.3270